Insider track record Other Across 7 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Explore the complete record of transactions filed by Neil Falkingham. Officer active across 1 company, notably GSK plc. Aggregated, 18 reports have been published. Activity tracked since 8 January 2026. The latest transaction was disclosed on 9 June 2026 (Purchase). Regulator: RNS (LSE). The full history is free.
Declarations 18 total
● PCA of Lynn Baxter (President, Europe) · Executives · 9 Jun 2026 · GSK plc 12 shares @ £18.8392 0.0000% mcap 0.0% of flow GB00BN7SWP63⌘ RNS:9614374-8 Ideal exit: 6 Mar 2027 (T+270) ● PCA of Lynn Baxter (President, Europe) · Executives · 9 Jun 2026 · GSK plc 12 shares @ £18.8392 0.0000% mcap 0.0% of flow GB00BN7SWP63⌘ RNS:03338973-0058-4811-9fe5-7b22157346a2-8 Ideal exit: 6 Mar 2027 (T+270) ● PCA of Lynn Baxter (President, Europe) · Executives · 12 May 2026 · GSK plc 14 shares @ £18.6557 0.0000% mcap 0.1% of flow GB00BN7SWP63⌘ RNS:eaad27f1-a91f-4bc4-815a-149202956de0-8 Ideal exit: 6 Feb 2027 (T+270) ● PCA of Lynn Baxter (President, Europe) · Executives · 13 Apr 2026 · GSK plc 12 shares @ £21.7083 0.0000% mcap 0.1% of flow GB00BN7SWP63⌘ RNS:bae2311e-28b0-4835-a894-0209eedccba9-8 Ideal exit: 8 Jan 2027 (T+270) ● PCA of Lynn Baxter (President, Europe) · Executives · 10 Apr 2026 · GSK plc 6 shares @ £21.6967 0.0000% mcap 0.0% of flow GB00BN7SWP63⌘ RNS:66208821-3d67-43ba-837e-411f45d449f1-3 Ideal exit: 5 Jan 2027 (T+270) ● PCA of Lynn Baxter (President, Europe) · Executives · 9 Apr 2026 · GSK plc 0
GB00BN7SWP63⌘ RNS:66208821-3d67-43ba-837e-411f45d449f1-15 Ideal exit: 4 Jan 2027 (T+270) ● PCA of Lynn Baxter (President, Europe) · Executives · 9 Apr 2026 · GSK plc 54 shares @ £21.3387 0.0000% mcap 0.2% of flow GB00BN7SWP63⌘ RNS:5b5d692c-e307-4a46-a436-f5464b4ee34b-9 Ideal exit: 4 Jan 2027 (T+270) ● PCA of Lynn Baxter (President, Europe) · Executives · 10 Mar 2026 · GSK plc 12 shares @ £20.7167 0.0% of flow GB00BN7SWP63⌘ RNS:08be650c-10c4-4fa5-9cae-5b89efa04716-8 Ideal exit: 5 Dec 2026 (T+270) ● PCA of Lynn Baxter (President, Europe) · Executives · 13 Feb 2026 · GSK plc 10,908 shares 0
GB00BN7SWP63⌘ RNS:9e068048-67e6-4a53-8636-ebe7180e6da4-28 ● PCA of Lynn Baxter (President, Europe) · Executives · 13 Feb 2026 · GSK plc 5,259 shares @ £21.6002 22.4% of flow GB00BN7SWP63⌘ RNS:9e068048-67e6-4a53-8636-ebe7180e6da4-29 ● PCA of Lynn Baxter (President, Europe) · Executives · 12 Feb 2026 · GSK plc 11,800 shares @ £21.41 49.9% of flow GB00BN7SWP63⌘ RNS:586c5c74-54b9-425a-a37c-ba21836ecce7-15 ● PCA of Lynn Baxter (President, Europe) · Executives · 9 Feb 2026 · GSK plc 10,050 shares 0
GB00BN7SWP63⌘ RNS:b9b234f0-beb3-4926-b79e-ff2ce727c5dd-10 ● PCA of Lynn Baxter (President, Europe) · Executives · 9 Feb 2026 · GSK plc 4,373 shares @ £21.9082 19.0% of flow GB00BN7SWP63⌘ RNS:b9b234f0-beb3-4926-b79e-ff2ce727c5dd-11 ● PCA of Lynn Baxter (President, Europe) · Executives · 10 Feb 2026 · GSK plc 12 shares @ £21.7917 0.1% of flow GB00BN7SWP63⌘ RNS:f7024c14-f781-4e48-a904-495085bc7ca2-8 Ideal exit: 7 Nov 2026 (T+270) ● PCA of Lynn Baxter (President, Europe) · Executives · 5 Feb 2026 · GSK plc 2,000 shares @ £20.87 8.3% of flow GB00BN7SWP63⌘ RNS:c409022d-25c5-4968-9022-97e323559e34-1 ● PCA of Lynn Baxter (President, Europe) · Executives · 8 Jan 2026 · GSK plc 53 shares @ £18.9432 0.2% of flow GB00BN7SWP63⌘ RNS:07b8fade-09b6-4441-a582-c78ac4e1b6b3-3 Ideal exit: 5 Oct 2026 (T+270) ● PCA of Lynn Baxter (President, Europe) · Executives · 8 Jan 2026 · GSK plc 0
GB00BN7SWP63⌘ RNS:07b8fade-09b6-4441-a582-c78ac4e1b6b3-13 Ideal exit: 5 Oct 2026 (T+270) ● PCA of Lynn Baxter (President, Europe) · Executives · 12 Jan 2026 · GSK plc 12 shares @ £18.9325 0.0% of flow GB00BN7SWP63⌘ RNS:07b8fade-09b6-4441-a582-c78ac4e1b6b3-43 Ideal exit: 9 Oct 2026 (T+270) About Neil Falkingham Neil Falkingham has filed 18 declarations in total. In the recent sample of filings we hold, purchases amount to EUR 4604 and sales to EUR 288829, with filings dated from 2026-01-13 to 2026-06-12. He is PCA of Lynn Baxter (President, Europe) at GSK plc.